Type 2 diabetes: Treatment goals and pharmaceutical therapies: Part two of a three-part roundtable discussion

Geriatrics

Volumn 53, Issue 4, 1998, Pages 42-51

  Butler, Robert N ^a,b   Rubenstein, Arthur H ^c   Gracia, Anne Marie G ^d   Zweig, Steven C ^e  

^a International Longevity Center   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^e University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; THIAZOLIDINE DERIVATIVE;

GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRESCRIPTION; REVIEW; TREATMENT INDICATION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; DRUG MONITORING; FAMILY PRACTICE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; PATIENT SELECTION; REFERRAL AND CONSULTATION;

EID: 0031707063     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (2)

1. Butler RN, Rubenstein AH, Gracia AG, Zweig SC. Type 2 diabetes: Causes, complications, and new screening recommendations. Geriatrics 1998; 53(March): 47-54.
2. Warner-Lambert Rezulin arm in NIH diabetes prevention trial is being retained; Glaxo troglitazone withdrawal in U.K. prompts re-evaluation of U.S. status. FDC Reports 1997; 59(49)(Dec 8):5-6.